Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study

Clinical Research in Cardiology

Volumn 104, Issue 1, 2015, Pages 31-37

  Simopoulos, V ^a   Tagarakis, G ^a   Hatziefthimiou, A ^a   Skoularigis, I ^a   Triposkiadis, F ^a   Trantou, V ^a   Tsilimingas, N ^a   Aidonidis, I ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Aldosterone antagonists; Cardiac surgery; Postoperative atrial fibrillation; Systolic heart failure

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; CHI SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS GRAFT; FEMALE; GREECE; HEART FAILURE, SYSTOLIC; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART SURGERY; HEART VALVE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; FEMALE; GREECE; HEART FAILURE, SYSTOLIC; HEART VALVES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84939881051     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0754-7     Document Type: Article

References (24)

1. Hogue CW, Hyder ML (2000) Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment. Ann Thorac Surg 69:300–306
2. Cao L, Li Q, Bi Q, Yu QJ (2011) Risk factors for recurrent stroke after coronary artery bypass grafting. J Cardiothorac Surg 23(6):157
3. Aidonidis I, Doulas K, Hatziefthimiou A et al (2013) Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits. J Cardiovasc Pharmacol Ther 18(1):94–101
4. Tagarakis GI, Aidonidis I, Daskalopoulou SS et al (2014) Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery. Curr Vasc Pharmacol 11(6):988–991
5. Swedberg K, Zannag F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in mild patients hospitalization and survival study in heart failure) study. Am Coll Cardiol 59(18):1598–1603
6. Lendeckel U, Dobrev D, Goette A (2010) Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol 159(8):1581–1583
7. Lammers C, Dartsch T, Brandt MC, Rottlander D, Halbach M, Peinkofer G et al (2012) Spironolactone prevents aldosterone induced increased duration of fibrillation in rat. Cell Physiol Biochem 29(5–6):833–840
8. Dabrowski R, Szwed H (2012) Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J 19(3):223–229
9. Shroff SC, Ryu K, Martovitz NL et al (2006) Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17(5):534–541
10. Workman AJ (2010) Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 381(3):235–249
11. Reil JC, Hohl M, Selejan S et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098–2108
12. Milliez P, Deangelis N, Rucker-Martin C et al (2005) Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26(20):2193–2199
13. Caballero R, Moreno I, Gonzalez T et al (2003) Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107:889–895
14. Workman AJ, Pau D, Redpath CJ et al (2009) Atrial cellular electrohysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm 6:445–451
15. Workman AJ, Kane KA, Russell JA et al (2003) Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evdence of pharmacological remodelling. Cardiovasc Res 58:518–525
16. + pump. Circulation Res 86:37–42
17. Lavall D, Selzer C, Schuster P et al (2014) The mineralcorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656–6668
18. Neuberger HR, Schotten U, Verheule S et al (2005) Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 111:30–37
19. Tsai CT, Chiang FT, Tseng CD et al (2010) Increased expression of mineralcorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55(8):758–770
20. Lampe B, Hamerstingl C, Schwab JO et al (2012) Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clin Res Cardiol 101(10):829–836
21. Neuberger HR, Cacciatore A, Reil JC et al (2012) Procollagen-propeptides: serum markers for atrial fibrosis? Clin Res Cardiol 101(8):655–661
22. Providencia R, Barra S, Paiva L (2013) Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clin Res Cardiol 102(10):701–711
23. Gregori M, Tocci G, Marra A, Pignatelli G et al (2013) Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clin Res Cardiol 102(10):725–733
24. Linz D, van Hunnik A, Ukena C et al (2014) Renal denervation: effects on atrial electrophysiology and arrhythmias. Clin Res Cardiol 115(3):400–409